

**FERMENTA BIOTECH (UK) LTD**  
**Independent auditors' report**  
**to the shareholder of FERMENTA BIOTECH (UK) LTD**

We have audited the accounts of FERMENTA BIOTECH (UK) LTD for the year ended 31 March 2014 which comprise the Profit and Loss Account, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and the Financial Reporting Standard For Smaller Entities (effective April 2008) (United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

**Respective responsibilities of directors and auditors**

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the accounts and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the accounts in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

In accordance with the exemption provided by APB Ethical Standard - Provisions Available for Smaller Entities (Revised), we have prepared and submitted the company's returns to the tax authorities and assisted with the preparation of the accounts.

**Scope of the audit opinion**

An audit involves obtaining evidence about the amounts and disclosures in the accounts sufficient to give reasonable assurance that the accounts are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the accounts.

**Opinion on the accounts**

In our opinion the accounts:

- give a true and fair view of the state of the company's affairs as at 31 March 2014 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities; and
- have been prepared in accordance with the requirements of the Companies Act 2006.


**Opinion on other matters prescribed by the Companies Act 2006**

In our opinion the information given in the Directors' Report for the financial year for which the accounts are prepared is consistent with the accounts.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the accounts are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the accounts and the directors' report in accordance with the small companies regime.



Harsh Kantilal Ondhia FCCA  
(Senior Statutory Auditor)  
for and on behalf of  
Lall Ondhia Ltd  
Accountants and Statutory Auditors  
23 May 2014

Charter House  
8-10 Station Road  
Manor Park  
London  
E12 5BT


**FERMENTA BIOTECH (UK) LTD**  
**Profit and Loss Account**  
**for the year ended 31 March 2014**

	Notes	2014 £	2013 £
Administrative expenses		(1,361)	(1,491)
<b>Operating loss</b>	2	<u>(1,361)</u>	<u>(1,491)</u>
<b>Loss on ordinary activities before taxation</b>		<u>(1,361)</u>	<u>(1,491)</u>
Tax on loss on ordinary activities		-	-
<b>Loss for the financial year</b>		<u><u>(1,361)</u></u>	<u><u>(1,491)</u></u>

**FERMENTA BIOTECH (UK) LTD****Balance Sheet****as at 31 March 2014**

	Notes	2014 £	2013 £
<b>Fixed assets</b>			
Intangible assets	3	156,876	156,876
<b>Current assets</b>			
Cash at bank and in hand		47,605	48,965
<b>Creditors: amounts falling due within one year</b>	4	(1,251)	(1,250)
<b>Net current assets</b>		46,354	47,715
<b>Net assets</b>		203,230	204,591
<b>Capital and reserves</b>			
Called up share capital	5	220,001	220,001
Profit and loss account	6	(16,771)	(15,410)
<b>Shareholder's funds</b>		203,230	204,591


The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.



Mr S Varma

Director

Approved by the board on 23 May 2014



Mr S Sharma

Director

**FERMENTA BIOTECH (UK) LTD**  
**Notes to the Accounts**  
**for the year ended 31 March 2014**

**1 Accounting policies**

***Basis of preparation***

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

***Deferred taxation***

Full provision is made for deferred taxation resulting from timing differences between the recognition of gains and losses in the accounts and their recognition for tax purposes. Deferred taxation is calculated on an un-discounted basis at the tax rates which are expected to apply in the periods when the timing differences will reverse.

***Foreign currencies***

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

<b>2 Operating profit</b>	<b>2014</b>	<b>2013</b>
	<b>£</b>	<b>£</b>
This is stated after charging:		
Auditors' remuneration	<u>750</u>	<u>750</u>
<b>3 Intangible fixed assets</b>		<b>£</b>
Research & Development Costs:		
<b>Cost</b>		
At 1 April 2013		<u>156,876</u>
At 31 March 2014		<u>156,876</u>
<b>Amortisation</b>		
At 31 March 2014		<u>-</u>
<b>Net book value</b>		
At 31 March 2014		<u>156,876</u>
At 31 March 2013		<u>156,876</u>

Research and development costs are recognised as an expense in the period in which they are incurred unless all of the criteria are met for asset recognition. The major asset recognition criteria includes that there is a clearly defined product or project, it has been assessed with reasonable certainty as to its technical feasibility and product or project's ultimate commercial viability. The aggregate of the deferred development costs and any further development costs is reasonably expected to be exceeded by related future sales or other revenues. Research and development costs are to be amortised over the estimated economic useful life.

All research and development costs have been capitalised for the current year and no amortization has been provided on the intangible fixed assets as the research and development work is in progress. The application for the patent protection recognition is pending and the management is reasonably expecting that the revenue from exploitation of the intellectual property rights will exceed the deferred development costs and any further development costs.

**FERMENTA BIOTECH (UK) LTD**  
**Notes to the Accounts**  
**for the year ended 31 March 2014**

		2014	2013
		£	£
<b>4 Creditors: amounts falling due within one year</b>			
Other creditors		<u>1,251</u>	<u>1,250</u>

		2014	2014	2013
		Number	£	£
<b>5 Share capital</b>	<b>Nominal value</b>			
Allotted, called up and fully paid:				
Ordinary shares	£1 each	220,001	<u>220,001</u>	<u>220,001</u>

<b>6 Profit and loss account</b>		2014
		£
At 1 April 2013		(15,410)
Loss for the year		(1,361)
		<u>(16,771)</u>
At 31 March 2014		

**7 Ultimate controlling party**

The holding company, Fermenta Biotech Ltd registered in India, controls the company by virtue of holding 100% of the issued shares capital.

**FERMENTA BIOTECH (UK) LTD**  
**Profit and Loss Account**  
**for the year ended 31 March 2014**  
*for the information of the directors only*

	<b>2014</b> <b>£</b>	<b>2013</b> <b>£</b>
Administrative expenses	(1,361)	(1,491)
<b>Operating loss</b>	<u>(1,361)</u>	<u>(1,491)</u>
<b>Loss before tax</b>	<u><u>(1,361)</u></u>	<u><u>(1,491)</u></u>

**FERMENTA BIOTECH (UK) LTD**  
**Schedule to the Profit and Loss Account**  
**for the year ended 31 March 2014**  
*for the information of the directors only*

	2014 £	2013 £
<b>Administrative expenses</b>		
General administrative expenses:		
Bank charges	<u>73</u>	<u>78</u>
	<u>73</u>	<u>78</u>
Legal and professional costs:		
Accountancy fees	<u>1,288</u>	<u>1,413</u>
	<u>1,288</u>	<u>1,413</u>
	<u>1,361</u>	<u>1,491</u>